Article
Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis.
The Journal of infection - 1 Jun 2018
Sanai Faisal M, Altraif Ibrahim H, Alswat Khalid, AlZanbagi Adnan, Babatin Mohamed A, AlMousa Abdallah, Almutairi Nawaf H, Aljawad Mohammed S, Alghamdi Abdullah S, Aljumah Abdulrahman A, Alalwan Abduljaleel M, Al-Hamoudi Waleed K, Assiri Abdullah M, Dahlan Yaser, Alsahafi Ashwaq, Alothmani Hammad S, AlSaleemi Mohammed S, Mousa Waleed A, Albenmousa Ali, Awny Abdelrahman, Albiladi Haziz, Abdo Ayman A, AlGhamdi Hamdan
Abstract excerpt
Limited clinical trial data has shown high efficacy of co-formulated ledipasvir/sofosbuvir (LDV/SOF) in the treatment of hepatitis C virus (HCV) genotype (GT)-4 infected cirrhotic patients. We assessed real-world safety and efficacy of LDV/SOF with or without ribavirin (RBV) in GT4-infected patients with compensated and decompensated cirrhosis. PATIENTS & METHODS: This observational cohort (n = 213) included GT4...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.